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Abstract. Because of emerging resistance to existing drugs, new chemical classes of antimalarial drugs are urgently
needed. We have rationally designed a library of compounds that were predicted to accumulate in the digestive vacuole
and then decrystallize hemozoin by breaking the iron carboxylate bond in hemozoin. We report the synthesis of
16 naphthothiazolium salts with amine-bearing side chains and their activities against the erythrocytic stage of Plasmodium
falciparum in vitro. KSWI-855, the compound with the highest efficacy against the asexual stages of P. falciparum in vitro,
also had in vitro activity againstP. falciparum gametocytes and in vivo activity against P. berghei in a murine malaria model.
INTRODUCTION
Plasmodium falciparum malaria kills up to one million per-
sons annually and accounts for up to 250 million clinical cases.1
Only drugs can be used to cure these potentially fatal infec-
tions.2 The efficacy of most currently used antimalarial drugs
has been compromised by the development of resistance.3 In
many different malaria-endemic areas, low to high-level resis-
tance in the predominant malaria parasites, Plasmodium
falciparum and P. vivax, has been observed for chloroquine,
amodiaquine, mefloquine, primaquine, and sulfadoxone-
pyrimethamine. As a result, the mainstay of antimalarial
treatment has become artemisinin combination therapies.
However, the efficacy of even this therapy has been threat-
ened by the emergence of delayed parasite response to
artemisinin combination therapies.4–9 Fortunately, significant
progress has been made to identify multiple new preclinical
leads and some promising compounds are in the early stages
of development.10 However, novel chemical classes of anti-
malarial compounds are still urgently needed to refresh the
pipeline of new and effective antimalarial drugs and sustain
progress in malaria control.11
Our goal was to design and test a novel chemical class of
antimalarial drugs using a rational structure based drug dis-
covery process. The hemoglobin degradation pathway is an
attractive antimalarial target because of its specificity and
necessity for parasite metabolism.12 The breakdown of host
hemoglobin, although essential for malaria parasite metabo-
lism, results in near molar levels of toxic-free heme that require
neutralization to prevent cellular damage. The heme moiety
consists of the porphyrin ring Fe(II)-protoporphyrin IX (FP),
which, as free FP, readily undergoes redox chemistry, thus
generating toxic free radicals and causing oxidative damage
via either the ferric ion co-ordinated in the heme moiety13 or
free hematin.14,15
To prevent host cell damage during intraerythrocytic growth,
the malaria parasite has evolved a unique survival mechanism
for detoxifying the heme groups: it crystallizes free heme
molecules into an insoluble crystalline material called
hemozoin. We have exploited the fact that P. falciparum is
dependent on hemozoin formation for survival to design a
new class of anti-malarial compounds that target this pathway.
We describe the synthesis and testing of a series of amphi-
philic napthothiazolium drugs for antimalarial activity. These
compounds were designed to bind heme via a stacking inter-
action with the porphyrin moiety of the heme to prevent
heme dimer formation and then decrystallize hemozoin by
reducing the Fe+3 in hemozoin to its Fe+2 oxidation state,
thereby breaking the iron carboxylate bonds holding the crystal
structure together. The most effective compound, KSWI-855
was evaluated in vitro against the asexual and sexual blood
stages of P. falciparum in vitro and against P. berghei in a
murine model of cerebral malaria.
MATERIALS ANDMETHODS
Chemistry. Chemical synthesis. 5-Hydroxynaptho[1,2-d]
thiazolium salts are conveniently prepared by reaction of a
suitably substituted thiourea derivative with a naphthoquinone
in ethanolic HCl (Figure 1A). Naphthothiazolium salts were
prepared by using the general procedure described.16 Synthe-
sis involves the reaction of a two-fold excess of a 1,4-quinone,
such as 2-methyl-1,4-naphthoquinone (menadione) with an
N-substituted or an N,N’-disubstituted thiourea derivative in
ethanol in the presence of one equivalent of hydrochloric acid
at room temperature in the dark, typically for 24–48 hours.
Products were characterized by 1H nuclear magnetic resonance
spectroscopy, elemental analysis, and melting point. Syntheses
of KSWI compounds 853, 854, 869, 870, 871, 872, 873, 874, and
875 was performed as described.16 For the remaining seven
compounds, the following syntheses are illustrative.
1-(3-Dimethylaminopropyl)-2-cyclohexylamino-5-hydroxy-
4-methylnaphtho[1,2-d]thiazolium chloride hydrochloride
(KSWI-855). The synthesis of KSWI-855 (Figure 1B) is
representative of the synthesis of the 1,N2-disubstituted
napthothiazolium derivatives KSWI-887, KSWI-888, and
KSWI 889. A solution of cyclohexyl isothiocyanate (5.65 g,
40 mmole) (Aldrich Chemicals, Milwaukee, WI) in disethyl
ether (15 mL) was added to a stirred solution of 3-dimethyla-
minopropylamine (4.2 g, 41 mmole) (Aldrich Chemicals) in
isopropanol (15 mL) with cooling in an ice bath. The mixture
was allowed to reach room temperature and was stirred for
16 hours. The crystalline N-cyclohexyl-N’-(3-dimethyla-
minopropyl)thiourea that separated was filtered and washed
with ether, yielding 7.3 g (75%) of white solid, melting
point = 62–67°C. A portion of this thiourea derivative
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(2.43 g, 10 mmole) was dissolved in ethanol (12.5 mL) contain-
ing aqueous concentration HCl (1.75 mL, 20 mmole). To this
stirred solution, a hot solution of 2-methyl-1,4-naphthoquinone
(3.44 g, 20 mmole) in ethanol (25 mL) was added. The hot
mixture was allowed to cool and was stored at room tempera-
ture in the dark for two days. The crude product that separated
was filtered and washed with ethyl acetate to yield 1.86 g
(40%) of crude product. Of this product, 1.5 g was recrystal-
lized by dissolving in 20 mL of hot ethanol and adding 120 mL
of warm acetone; the white powder that separated on cooling
was filtered and washed with ethyl acetate to give 1.14 g (30%)
of KSWI-855, melting point = 250–255°C (with decomposition).
2-(3-(4-Morpholino)propylamino)-4-methyl-5-hydroxynaphtho
[1,2-d]thiazolium chloride hydrochloride (KSWI-878).A solu-
tion of N-(3-(4-Morpholino)propylamino)thiourea (1.016 g,
5 mmole) (Trans World Chemicals Inc., Rockville, MD) in
ethanol (5 mL) was added to a suspension of 2-methyl-1,4-
naphthoquinone (1.72 g, 10 mmole) in ethanol (Figure 1C).
The mixture was treated with concentrated aqueous HCl
(0.83 mL, 10 mmole) and heated until dissolved. The mixture
was allowed to cool and was stored for three days at room
temperature in the dark. The solvent was removed in vacuo
and the residue was triturated with 1:1 ethanol-ethyl acetate.
The light pink-tan powdery solid was filtered and dried
(weight = 1.479 g). Recrystallization of 1.0 g by dissolving in
50 mL of hot methanol and diluting with 100 mL warm ethyl
acetate gave on filtration and drying the title compound as
0.883 g (63%) of off-white powder, melting point = 266–270°C
(with decomposition).
2-[[3-[1-[2- (aminoiminomethyl) hydrazono]ethyl]phenyl]-
amino]-4-methylnaphthol[1,2-d]thiazol-5-ol dihydrochloride
(KSWI-856). 3-acetylaniline (6.76 g, 50 mmole) in ethanol
(50 mL) was treated with methyl isothiocyanate (3.42 mL,
50 mmole). After stirring for 18 hours at room temperature,
the crystalline N-(3-acetylphenyl)-N¢-methylthiourea product
was filtered (7.75 g, 75% yield, melting point = 119–120°C).
This thiourea (3.5 g, 16.8 mmole) was combined with
2-methylnaphthoquinone (5.8 g, 33.6 mmole) in 35mL of ethanol
in the presence of 12N aqueous HCl (1.4 mL, 16.8 mmole).
After 24 hours, filtration and washing with ethanol, ethyl
acetate, and ether and air drying gave 2-(3-acetylphenyl)
amino-1,4-dimethyl-5-hydroxynaphtho[1,2-d]thiazolium chlo-
ride (1.62 g, 24%). This keto naphthothiazolium salt (0.80 g,
2.0 mmole) was heated at reflux in 80% methanol (12 mL)
containing aminoguanidine hydrochloride (0.24 g, 2.2 mmole)
for 40 hours and allowed to cool. Filtration yielded 0.80 g of an
off-white powder. Recrystallization of 0.75 g from methanol
gave 0.42 g the title compound as a pale yellow powder, melt-
ing point 252–257°C (with decomposition).
8-[1-[2-(aminoiminomethyl) hydrazono]ethyl]- 2-(butylimino)-
1,2-dihydro-1,4- dimethylnaphtho[1,2-d]thiazol-5-ol monohydro-
chloride (KSWI-886). 6¢-Methyl-2¢-acetonaphthone (5.52 g,
30 mmole) (Aldrich Chemicals) (5.52 g, 30 mmole) in acetic
acid (22 mL) was treated dropwise with a solution of chro-
mium trioxide (15 g, 150 mmole) in aqueous 45% (v/v) acetic
acid (20 mL) with stirring and cooling in a 25°C water bath.
After stirring for 16 hours at room temperature, the mixture
was diluted with 200 mL of water. The yellow solid that
Figure 1. A, Synthesis of napthothiazolium. Naphthothiazolium salts, were prepared by mixing a two-fold excess of a 1,4-quinone, such as
2-methyl-1,4-naphthoquinone (menadione), with an N-substituted or an N,N¢-disubstituted thiourea derivative in ethanol in the presence of one
equivalent of hydrochloric acid at room temperature in the dark, typically for 24–48 hours. B, Synthesis of KSWI-855. Cyclohexyl isothiocyanate in
diethyl ether was added to dimethylaminopropylamine in isopropanol. The resultant crystalline N-cyclohexyl-N¢-(3-dimethylaminopropyl)thiourea
was subsequently mixed with 2-methyl-1,4-naphthoquinone to form 1-(3-dimethylaminopropyl)-2-cyclohexylamino-5-hydroxy-4-methylnaphtho
[1,2-d]thiazolium chloride hydrochloride (KSWI-855). C, Synthesis of KSWI-878. N-(3-(4-morpholino)propylamino)thiourea in ethanol was added
to 2-methyl-1,4-naphthoquinone in ethanol to form 2-(3-(4-morpholino)propylamino)-4-methyl-5-hydroxynaphtho[1,2-d]thiazolium chloride
hydrochloride (KSWI-878).
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separated was filtered and recrystallized from isopropanol
(40 mL) to give 6-acetyl-2-methyl-1,4-naphthoquinone (2.82 g,
44%, melting point = 126°C). This quinone (1.284 g, 6.0 mmole)
was combined with N-butyl-N’-methylthiourea (52) (0.584 g,
4 mmole) in ethanol (20 mL), treated with 12N HCl (0.34 mL,
4 mmole), heated to reflux, and allowed to cool. After 42 hours
at room temperature, filtration gave 8-acetyl-2-butylamino-1,4-
dimethyl-5-hydroxynaphtho[1,2-d]thiazolium chloride (0.515 g,
34%). This keto thiazolium salt (0.284 g, 0.75 mmole) was
heated at reflux with aminoguanidine HCl (0.110 g, 1 mmole)
in aqueous 85% ethanol (7 mL) for 44 hours. Cooling and
filtration gave KSWI-886 (0.170 g, 48%, melting point = 260–
264°C (with decomposition).
In vitro testing using P. falciparum asexual stages.
Plasmodium falciparum chloroquine-sensitive strain D10 and
chloroquine-resistant strainDd2were grown inA+ human eryth-
rocyte suspensions using RPMI 1640 (GIBCO, Gaithersburg,
MD) medium supplemented with 25 mM HEPES (pH 7.35),
0.2% NaHCO3 (23 mM), 0.2% (D)-glucose, and 10% human
A+ plasma and maintained at 37°C in candle jars. Cultures
were synchronized to within 4–6 hours of each other by
treating cultures with 5% D-sorbitol to select for ring stages.
Parasite growth was determined by measuring incorporation
of 3H-hypoxanthine into the nucleic acids of the parasite as
described.17 Compound IC50 values (molar concentration that
decreases 3H-hypoxanthine incorporation by 50% compared
with compound-free controls) were calculated by extrapola-
tion of the log dose-response curves by using curve fitting
software (Origin; Microcal Software, Northampton, MA).
In vitro testing using P. falciparum gametocytes. To test
the effect of drugs on gametocyte stages, P. falciparum NF54
cultures were initiated in 24-well plates at 0.5% asexual
parasitemia and 4% hematocrit.18 Medium was changed daily
up to day 18, without addition of fresh erythrocytes. Continu-
ous cultivation without dilution leads to concomitant crash of
asexual parasitemia and induction of gamteocytogenesis by
day 5. The gametocytemia was approximately 6% at start of
treatment. Drugs were dosed in wells at days 14 and 15 when
most gametocytes have matured to stages III–V. Levels of
gametocytemia were determined on day 18 and the mean
number of gametocytes was calculated by counting 10 high-
powered (1,000 +) fields from triplicate wells per condition.
More than 500 erythrocytes were enumerated by random
scanning across a Giemsa-stained blood film.
In vivo testing using P. berghei. C57Bl/6 mice were injected
on day 0 with 106 P. berghei (MRA-865).19 Mice (n = 6 mice/
group) were dosed intraperitoneally with each of the com-
pounds (KSWI-854, 855, 887, 888, and 889) by using 25 mg/kg,
10 mg/kg, or 1 mg/kg at each of the following time points after
infection: 2, 24, 48, and 72 hours. Blood smears were prepared
on day 4 (96 hours post-infection) and stained with Giemsa.
Parasitemia was assessed by counting the number of infected
erythrocytes per 1,000 total erythrocytes.
RESULTS
Activity against chloroquine sensitive and multi-drug
resistant P. falciparum strains in vitro. A panel of sixteen
5-hydroxynaptho[1,2-d]thiazolium salts napthothiazolium
salts were synthesized. Compounds were first tested in vitro
against chloroquine-sensitive P. falciparum (strain D10, IC50
for chloroquine = 15–30 nM20,21). As shown in Table 1, ten of
the compounds, KSWI-854, 855, 856,869, 872, 878, 886, 887,
888, and 889, displayed potent activity in vitro and showed
IC50 values £ 1 mM. The most effective compound, KSWI-
855, had an IC50 of 75 nM. All of the active compounds have
their amine-bearing side chain attached to the sterically
crowded ring nitrogen. Lower activity was associated with
absence of a side chain bearing a distal amine.
Five of the active compounds were further evaluated for
activity against a multi-drug resistant P. falciparum strain
(strain Dd2, IC50 for chloroquine = 60–160 nM
20,22,23). IC50
values ranging from 500 nM to 75 nM for KSWI-854 and
KSWI-855, respectively, were obtained. KSWI-855, [2-
(cyclohexylimino)-1,2-dihydro-4-methyl-1-[3-(dimethylamino)
propyl]naphtho-[1,2-d]thiazol-5-ol dihydrochloride], was the
most active compound against the chloroquine-sensitive
P. falciparum strain (D10) and the multi-drug resistant strain
(Dd2). KSWI-855 was further evaluated for activity against
P. falciparum gametocytes stages III–V in vitro and showed
modest efficacy. As shown in Figure 2, 47% of the late stage
gametocytes were killed at a concentration of 4 uM. Although
stage III–IV gametocytes (strain NF54) are generally less sen-
sitive to antimalarial agents, they are sensitive to chloroquine
at micromolar concentrations.
Activity against P. berghei in vivo. The five compounds
with the lowest IC50 values in vitro against P. falciparum, were
subsequently tested in vivo against the mouse malaria parasite
P. berghei in a murine model of cerebral malaria.24 Each
compoundwas injected intraperitoneally at 2, 24, 48, and 72 post-
infection at a concentration of 25 mg/kg. Peripheral blood
smears were prepared on day 4 (96 hours post-infection) and
parasitemia was assessed (Table 2). All compounds were active,
although none cleared the parasitemia by day 4. KSWI-855
continued to be the most active compound and inhibited
parasitemia by 84% on day 4. Survival was assessed in the
mice through day 15. At day 15, survival in the untreated mice
was 0%, 66% in the mice treated with KSWI-889 and 100% in
the mice treated with KSWI-854, 855 and 888.
In addition, the efficacy of lower dosages of KSWI-855 and
854 was tested by administering each compound intraperito-
neally at 2, 24, 48, and 72 hours post-infection at 10 mg/kg or
1 mg/kg. For both compounds, 10 mg/kg was more active than
1 mg/kg and there was an observed reduction in the mortality
rate, but none of the treatments cured the mice. Treatment
with KSWI-854 at a concentration of 10 mg/kg resulted in
survival of 100% of the mice. Treatment with either KSWI-
855 at a concentration of 10 mg/kg or KSWI-854 at a concen-
tration of 1 mg/kg resulted in 80% survival, and treatment
with KSWI- 855 at a concentration of 1 mg/kg resulted in
60% survival (Figure 3). KSWI-855 had no antimalarial activity
when administered orally at a concentration of 25 mg/kg at 2,
24, 48, and 72 hours post-infection.
DISCUSSION
We describe the antimalarial activity of amphiphilic
naphthothizolium salts with amine-bearing side chains. The
most active compound, KSWI-855, has an IC50 of 75 nM
against the chloroquine-sensitive P. falciparum (strain D10)
and the multi-drug resistant P. falciparum (strain Dd2) and
4 mM against late stage (stages III–V) P. falciparum gameto-
cytes. In addition, KSWI-855 demonstrates antimalarial activity
826 ULRICH AND OTHERS
Table 1
Activity of napthothiazolium salts against Plasmodium falciparum in vitro*
Structure Compound number and chemical name IC50 vs. P. falciparum
KSWI-853
1-ethyl-2-(ethyl-imino)-1,2-dihydro-4-methyl-
naphtho[1,2-d]thiazol-5-ol monohydrochloride
2.5 mM CQS
KSWI-854
1,2-dihydro-1,4-dimethyl-2-[[3-(4-methyl-1-piperazinyl)
propyl]imino]naphtho[1,2-d]- thiazol-5-ol trihydrochloride
0.075 mM CQS
0.5 mM CQR
KSWI-855
2-(cyclohexylimino)-1,2-dihydro-4-methyl-1-[3- (dimethylamino)
propyl]naphtho- [1,2-d]thiazol-5-ol dihydrochloride
0.075 mM CQS
0.075 mM CQR
KSWI-856
2-[[3-[1-[2- (aminoiminomethyl) hydrazono]ethyl]phenyl]-
amino]-4-methylnaphthol[1,2-d]thiazol-5-ol dihydrochloride
0.83 mM CQS
KSWI-869
2-[[3-[bis(2-hydroxyethyl)amino] propyl]imino]-
1,2-dihydro-1,4-dimethylnaphtho[1,2-d]- thiazol-5-ol dihydrochloride
0.2 mM CQS
KSWI-870
1,2-dihydro-4-methyl-1-(2-propenyl)-2-
(2- propenylimino)naphtho[1,2-d]thiazol-5-ol monohydrochloride
6.0 mM CQS
KSWI-871
4-methyl-2-(2-propenylamino) naphtho[1,2-d]-
thiazol-5-ol monohydrochloride
6.3 mM CQS
KSWI-872
2-(cyclohexylimino)-5-hydroxy-4-methyl-naphtho[1,2-d]thiazole-
1(2H)-ethanol monohydrochloride
1.0 mM CQS
KSWI-873
1,2-dihydro-2-[(2-hydroxyethyl)imino]-1,4-di-
methylnaphtho[1,2-d]thiazol-5-ol monohydrochloride
1.4 mM CQS
KSWI-874
1,2-dihydro-1,4-dimethyl-2-(phenylimino)-
naphtho[1,2-d]thiazol-5-ol monohydrochloride
10 mM CQS
(continued)
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in vivo in a murine model of malaria when administered intra-
peritoneally but not if dosed orally.
This series of compounds was designed to hypothetically
accumulate in the digestive vacuole of the malaria parasite
and catalyze the decrystallization of hemozoin. Hemozoin is
found in all species of Plasmodium, including all the currently
known human pathogens (P. falciparum, P. vivax, P. ovale,
P. malariae, and P. knowlesi.25 Hemozoin can be found in
all of the erythrocytic stages of the parasite, including the
late-stage metabolically inactive stage V gametocytes. The
hemoglobin degradation pathway is an attractive antimalarial
target because of its specificity and necessity for parasite
metabolism.26 As the P. falciparum parasite grows inside the
host erythrocyte, it digests and metabolizes up to 80% of the
erythrocyte hemoglobin in the parasitic food vacuole.27 Hemo-
globin is hydrolyzed by a multiprotein complex containing
aminopeptidases, aspartic proteases (plasmepsins), and cysteine
proteases (falcipains).28,29 This degradation of large amounts
of hemoglobin is believed to be critical to provide a source
of amino acids and to help maintain intracellular osmolarity
during rapid parasite growth.30 However, the breakdown of
TABLE 1
Continued
Structure Compound number and chemical name IC50 vs. P. falciparum
KSWI-875
1,2-dihydro-4-methyl-2-(phenylimino)naphtho-
[1,2-d]thiazol-5-ol monohydrochloride
4.2 mM CQS
KSWI-878
4-methyl-2-[[3-(4-morpholino)propylamine]-
naphtho[1,2-d]thiazol-5-ol dihydrochloride
0.6 mM CQS
KSWI-886
8-[1-[2-(aminoiminomethyl) hydrazono]ethyl]-
2-(butylimino)-1,2-dihydro-1,4-
dimethylnaphtho[1,2-d]thiazol-5-ol monohydrochloride
0.6 mM CQS
KSWI-887
2-(cyclohexylimino)-1,2-dihydro-4-methyl-1-
[3-(4-morpholino)propyl]naphtho[1,2-d]thiazol-5-ol dihydrochloride
0.33 mM CQS
0.19 mM CQR
KSWI-888
2-(cyclohexylimino)-1,2-dihydro-4-methyl-1-
[3-(4-methyl-1-piperazinyl)propyl]naphtho[1,2-d]
thiazol-5-ol trihydrochloride
0.16 mM CQS
0.17 mM CQR
KSWI-889
2-[[3-(dimethylamino)propyl]imino]-1,2-dihydro-1,
4-dimethylnaphtho[1,2-d]thiazol-5-ol dihydrochloride
0.21 mM CQS
0.25 mM CQR
* Compounds were screened in vitro for activity against P. falciparum chloroquine-sensitive strain D10 (CQS) and P. falciparummultidrug-resistant strain Dd2 (CQR) in a 96-hour growth assay.
Parasite growth was determined by measuring incorporation of 3H-hypoxanthine into the nucleic acids of the parasite. IC50 values are the molar drug concentrations that decrease
3H-hypoxanthine
incorporation by 50% compared with drug-free samples.
Figure 2. Activity of KSWI 855 against late stage Plasmodium
falciparum gametocytes. On days 14–15 after initiation of gameto-
cytes, increasing concentrations of KSWI-855 were effective at killing
stage III–V gametocytes. On day 18, no drug control wells numbered
6.1% gametocytes per total cells of more than 500 cells counted in
replicate wells. Data are expressed as percent inhibition of control
wells. Error bars indicate 95% confidence intervals.
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host hemoglobin, results in near molar levels of toxic-free heme.
The heme moiety, consisting of the porphyrin ring Fe(II)-
protoporphyrin IX (FP), can readily undergo redox chemistry,
generate toxic free radicals, and cause oxidative damage.13,31
To prevent host cell damage during intraerythrocytic growth,
the malaria parasite has evolved a unique survival mechanism
for detoxifying heme: it crystallizes free heme molecules into
hemozoin, an insoluble crystalline material.32
It has proven difficult to obtain an x-ray diffraction pattern
of native hemozoin, but the structure of its synthetic analogue,
b-hematin, has been solved definitively by x-ray powder dif-
fraction pattern.33 b-Hematin is not a polymer of single heme
units as had been believed,34 but rather it is composed of
cyclic dimers of Fe+3-protoporphyrin IX in which one propio-
nate group of each Fe+3-PPIX molecule coordinates to the
Fe+3 center of its partner, and the dimers are linked through
hydrogen bonding of the other propionic acid groups.33 The
iron-carboxylate bonds in hemozoin, which are critical to the
stability of the polymer, are stable only when the iron is in
the Fe+3 state. This information encouraged us to attempt the
design of compounds that could hypothetically decrystallize
hemozoin. The chemical challenge of this problem is formida-
ble because the only known solubilizing agent for hemozoin is
strong alkali (0.1 N NaOH).
We designed compounds that are predicted to change from
complete neutrality from their initial multi-protonated state:
The 2-amino group on the thiazolium ring has a relatively
low pKa and can be reversibly deprotonated to a neutral
thiazolone imine with concurrent deprotonation of the
other side chain amine(s). We postulated that the planar
naphthothiazolium ring structure in these compounds could
align geometrically with the heme group in hemozoin through
the formation of pi-pi complexes while the amine-bearing
side chain interacted with a heme carboxylate side chain
Table 2
Activity of naphthothiazolium salts against Plasmodium berghei in vivo*
Compound number and chemical name Structure
% Inhibition of
parasitemia on day 4
% Survival
on day 15
KSWI-854
1,2-dihydro-1,4-dimethyl-2-[[3-(4-methyl-1-piperazinyl)
propyl]imino]naphtho[1,2-d]- thiazol-5-ol trihydrochloride
79 100
KSWI-855
2-(cyclohexylimino)-1,2-dihydro-4-methyl-1-[3- (dimethylamino)
propyl]naphtho- [1,2-d]thiazol-5-ol dihydrochloride
84 100
KSWI-887
2-(cyclohexylimino)-1,2-dihydro-4-methyl-1-[3-
(4-morpholino)propyl]naphtho[1,2-d]thiazol-5-ol dihydrochloride
49 0
KSWI-888
2-(cyclohexylimino)-1,2-dihydro-4-methyl-1-[3-(4-methyl-1-
piperazinyl)propyl]naphtho[1,2-d]thiazol-5-ol trihydrochloride
82 100
KSWI-889
2-[[3-(dimethylamino)propyl]imino]-1,2-dihydro-1,4-
dimethylnaphtho[1,2-d]thiazol-5-ol dihydrochloride
82 66
* Compounds were screened for in vivo activity by using five berghei. C57Bl/6 mice were injected on day 0 with 106 parasitized erythrocytes and then dosed intraperitoneally with 25 mg/kg of the
indicated drug at each of the following time points: 2, 24, 48, and 72 hours (n = 6 mice/group). Peripheral blood smears were prepared on day 4 and parasitemia was determined. Mice were
monitored daily for 15 days. Inhibition of parasitemia on day 4 = 100 – ([mean parasitemia treated/mean parasitemia control] + 100).16 Percent survival is the percentage of mice that were alive
at day 15 post-infection. The five most active compounds are shown.
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(Figure 4A). This reaction would place a naphtholic hydroxyl
group near the heme-Fe3+ (Figure 4B), where it can reduce
the iron atom to Fe2+, thereby dissociating the heme monomer
from its hemozoin neighbor, releasing free heme (Figure 4C).
We hypothesize that these amphiphilic compounds are able
to reversibly enter the hemozoin-containing lipid nanospheres
inside the parasite and then decrystallize hemozoin by reducing
the Fe+3 in hemozoin to its Fe+2 oxidation state, thereby break-
ing the iron carboxylate bonds holding the crystal structure
together to release free heme. Work is currently on-going to
evaluate this hypothetical mechanism of action and to modify
KSWI-855 to increase its hydrophilicity and bioavailability.
In conclusion, we have described the chemical synthesis
and the initial characterization of a new chemical class of
antimalarial compounds, the napthothiazolium salts, which
have efficacy similar to chloroquine. Further studies may lead
to the developed of orally active analogues that may be useful
for the treatments of acute P. falciparum and P. vivax infec-
tions and to reduce malaria transmission.
Figure 3. Dose effect of KSWI-855 and KSWI-854 in vivo in a
Plasmodium berghei malaria model. C57Bl/6 mice were infected intra-
peritoneally with 2 + 107 P. berghei parasitized erythrocytes. KSWI-
854 and KSWI-855 were injected intraperitoneally with 10 mg/kg or
1 mg/kg at 2, 24, 48, and 72 hours post-infection (n = 6 mice/group).
Data for treatment groups was compared with that of the saline
control group and analyzed by sing the log-rank (Mantel-Cox) test.
**KSWI-854 (10 mg/kg): P = 0.0015. **KSWI-54 (1 mg/kg): P = 0.008.
* KSWI-855 (10 mg/kg): P = 0.0374. KSWI-55 (1 mg/kg): P = 0.0807.
Figure 4. Theoretical mechanism of action. A, Planar ring of naphthothiazolium salts align with the heme group in hemozoin. B, Hydroxyl
group nucleophilically attacks the heme-Fe3+ in the iron carboxylate bond of hemozoin. C, Reduction of heme-Fe3+ to form Fe2+ then catalyzes
the breakdown of hemozoin through nucleophilic attack of the Fe3+-carboxylate bond.
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